دورية أكاديمية
N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications.
| العنوان: | N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications. |
|---|---|
| المؤلفون: | Wang Y; Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China., Zou J; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China., Zhou H; Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China. |
| المصدر: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Sep 04; Vol. 15, pp. 1462146. Date of Electronic Publication: 2024 Sep 04 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Epigenesis, Genetic* , Diabetic Angiopathies*/genetics , Diabetic Angiopathies*/metabolism, Humans ; Animals ; Methylation ; Adenine/analogs & derivatives ; Diabetes Mellitus/genetics ; Diabetes Mellitus/metabolism ; RNA Methylation |
| مستخلص: | N6-methyladensine (m 6 A) has been identified as the best-characterized and the most abundant mRNA modification in eukaryotes. It can be dynamically regulated, removed, and recognized by its specific cellular components (respectively called "writers," "erasers," "readers") and have become a hot research field in a variety of biological processes and diseases. Currently, the underlying molecular mechanisms of m 6 A epigenetic modification in diabetes mellitus (DM) and diabetic microvascular complications have not been extensively clarified. In this review, we focus on the effects and possible mechanisms of m 6 A as possible potential biomarkers and therapeutic targets in the treatment of DM and diabetic microvascular complications. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Wang, Zou and Zhou.) |
| References: | Nat Commun. 2016 Aug 25;7:12626. (PMID: 27558897) Front Endocrinol (Lausanne). 2022 Sep 08;13:997034. (PMID: 36157472) Nat Metab. 2019 Aug;1(8):765-774. (PMID: 31867565) Diabetes Res Clin Pract. 2023 Apr;198:110607. (PMID: 36878322) Lancet Neurol. 2022 Oct;21(10):922-936. (PMID: 36115364) Metabolism. 2021 Mar;116:154702. (PMID: 33417895) Life Sci. 2024 Feb 15;339:122421. (PMID: 38232799) Lancet Diabetes Endocrinol. 2023 Nov;11(11):848-860. (PMID: 37804855) Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167022. (PMID: 38216068) Front Pharmacol. 2021 Jul 15;12:667644. (PMID: 34335245) J Nephrol. 2022 Jul;35(6):1571-1584. (PMID: 35201595) Food Funct. 2019 Jan 22;10(1):216-223. (PMID: 30534761) Nutrients. 2023 Apr 11;15(8):. (PMID: 37111057) PLoS Genet. 2007 Jul;3(7):e115. (PMID: 17658951) Mol Immunol. 2022 Apr;144:16-25. (PMID: 35168108) Cells. 2022 Mar 24;11(7):. (PMID: 35406663) Nat Commun. 2017 May 16;8:15296. (PMID: 28508859) Metabolism. 2023 Jan;138:155339. (PMID: 36302453) Front Cell Neurosci. 2018 May 23;12:139. (PMID: 29875633) Science. 2015 Feb 27;347(6225):1002-6. (PMID: 25569111) Stem Cell Res Ther. 2017 Nov 2;8(1):240. (PMID: 29096722) Clin Transl Med. 2022 Jun;12(6):e942. (PMID: 35731980) J Clin Endocrinol Metab. 2015 Jan;100(1):E148-54. (PMID: 25303482) Mol Cell. 2022 May 5;82(9):1678-1690.e12. (PMID: 35305312) Trends Endocrinol Metab. 2014 Dec;25(12):628-36. (PMID: 25246382) Protein Cell. 2020 Nov;11(11):792-808. (PMID: 32440736) Mol Ther. 2020 Oct 7;28(10):2191-2202. (PMID: 32755566) Mol Cell. 2019 May 16;74(4):640-650. (PMID: 31100245) J Diabetes Investig. 2024 Mar;15(3):288-299. (PMID: 38013600) Mol Biomed. 2023 Aug 24;4(1):25. (PMID: 37612540) Front Endocrinol (Lausanne). 2023 Jul 07;14:1166756. (PMID: 37484964) Fundam Res. 2021 Dec 24;2(1):56-58. (PMID: 38933901) Curr Opin Nephrol Hypertens. 2015 Jul;24(4):345-50. (PMID: 26050121) Cell. 2015 Jun 4;161(6):1388-99. (PMID: 26046440) Discov Med. 2022 Sep-Oct;34(172):115-129. (PMID: 36333113) Cancer Lett. 2021 Oct 10;518:196-206. (PMID: 34271104) J Biochem Mol Toxicol. 2024 Jan;38(1):e23621. (PMID: 38229320) Sci Transl Med. 2019 Apr 17;11(488):. (PMID: 30996080) J Diabetes. 2013 Jun;5(2):136-45. (PMID: 23298195) FASEB J. 2024 Jun 15;38(11):e23729. (PMID: 38847786) Elife. 2017 Oct 06;6:. (PMID: 28984244) Nucleic Acids Res. 2017 Nov 2;45(19):11356-11370. (PMID: 28977517) Signal Transduct Target Ther. 2021 Feb 21;6(1):74. (PMID: 33611339) Aging (Albany NY). 2020 May 4;12(9):8137-8150. (PMID: 32365051) ACS Chem Biol. 2022 Jul 15;17(7):1778-1788. (PMID: 35708211) Biochem Biophys Res Commun. 2019 Oct 8;518(1):120-126. (PMID: 31405565) Exp Cell Res. 2018 Sep 15;370(2):333-342. (PMID: 29964051) J Biol Chem. 2021 Aug;297(2):100973. (PMID: 34280435) PLoS One. 2015 May 27;10(5):e0127705. (PMID: 26018652) Diabetes. 2009 Jun;58(6):1440-4. (PMID: 19258437) EMBO Rep. 2021 May 5;22(5):e52146. (PMID: 33880847) Pharmacol Res. 2021 Aug;170:105713. (PMID: 34098071) J Diabetes. 2014 Nov;6(6):535-40. (PMID: 24720446) Mol Metab. 2021 Jun;48:101209. (PMID: 33705986) Exp Mol Med. 2024 Feb;56(2):355-369. (PMID: 38297163) Autophagy. 2024 May;20(5):1072-1097. (PMID: 38050963) Genomics. 2022 Nov;114(6):110498. (PMID: 36174881) Diabetes. 2024 Feb 1;73(2):237-249. (PMID: 37963393) Cell Death Dis. 2018 Jul 23;9(8):796. (PMID: 30038300) Cells. 2022 Apr 26;11(9):. (PMID: 35563766) Exp Eye Res. 1996 Feb;62(2):155-69. (PMID: 8698076) Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063. (PMID: 28334903) Med Hypotheses. 2019 Apr;125:79-83. (PMID: 30902156) Proc Natl Acad Sci U S A. 1974 Oct;71(10):3971-5. (PMID: 4372599) J Biochem Mol Toxicol. 2024 Jan;38(1):e23596. (PMID: 38088496) Front Endocrinol (Lausanne). 2023 Jul 07;14:1223583. (PMID: 37484960) Cancer Cell Int. 2021 Feb 16;21(1):109. (PMID: 33593354) Environ Toxicol. 2023 Nov;38(11):2772-2782. (PMID: 37551785) J Clin Invest. 2023 Oct 2;133(19):. (PMID: 37781923) Trends Pharmacol Sci. 2023 Jun;44(6):335-353. (PMID: 37069041) Front Endocrinol (Lausanne). 2023 Jan 09;13:1077669. (PMID: 36699020) Acta Diabetol. 2023 Mar;60(3):387-399. (PMID: 36574062) Cell Death Dis. 2021 Jan 4;12(1):32. (PMID: 33414476) Biomed Res Int. 2022 Apr 26;2022:2677312. (PMID: 35528183) J Invest Dermatol. 2024 May;144(5):1148-1160.e15. (PMID: 38242315) Cell Res. 2014 Feb;24(2):177-89. (PMID: 24407421) Mol Cell Endocrinol. 2018 Sep 5;472:10-17. (PMID: 29890211) Pharmacol Res. 2022 Apr;178:106135. (PMID: 35192956) Cell. 2020 Jun 25;181(7):1582-1595.e18. (PMID: 32492408) Genomics Proteomics Bioinformatics. 2020 Aug;18(4):371-383. (PMID: 33160098) Nutr Metab (Lond). 2023 Sep 15;20(1):40. (PMID: 37710320) Int J Mol Sci. 2021 Feb 22;22(4):. (PMID: 33671635) Front Endocrinol (Lausanne). 2022 Jul 08;13:910868. (PMID: 35872977) Diabetologia. 2008 Sep;51(9):1659-63. (PMID: 18618095) Biochem Biophys Res Commun. 2019 Oct 22;518(4):678-684. (PMID: 31472957) BMC Med Genet. 2010 May 28;11:81. (PMID: 20509872) Cell. 2015 Sep 10;162(6):1299-308. (PMID: 26321680) Kidney Int. 2022 Nov;102(5S):S1-S127. (PMID: 36272764) Med Clin North Am. 2023 Jul;107(4):689-705. (PMID: 37258007) Exp Eye Res. 2022 Sep;222:109152. (PMID: 35714699) J Pathol. 2013 May;230(1):95-106. (PMID: 23299523) Diabetes. 2020 Aug;69(8):1708-1722. (PMID: 32404350) Obes Rev. 2023 Dec;24(12):e13639. (PMID: 37732463) Front Endocrinol (Lausanne). 2022 Sep 08;13:866116. (PMID: 36157445) Int Immunopharmacol. 2023 Apr;117:109910. (PMID: 37012886) Nature. 2009 Apr 16;458(7240):894-8. (PMID: 19234441) Signal Transduct Target Ther. 2022 Nov 7;7(1):374. (PMID: 36336680) J Diabetes. 2017 May;9(5):434-449. (PMID: 28044409) Nat Chem Biol. 2014 Feb;10(2):93-5. (PMID: 24316715) J Hematol Oncol. 2020 Apr 10;13(1):35. (PMID: 32276589) Mol Cell. 2022 May 5;82(9):1608-1609. (PMID: 35523125) Trends Endocrinol Metab. 2023 Feb;34(2):66-84. (PMID: 36586778) Commun Biol. 2022 Feb 10;5(1):124. (PMID: 35145192) Nat Struct Mol Biol. 2016 Feb;23(2):98-102. (PMID: 26840897) Mol Med. 2021 Nov 13;27(1):146. (PMID: 34773968) Front Immunol. 2022 Mar 01;13:813979. (PMID: 35300330) Nat Commun. 2018 Jan 29;9(1):420. (PMID: 29379020) Theranostics. 2022 Jan 1;12(1):277-289. (PMID: 34987645) Nat Genet. 2010 Dec;42(12):1086-92. (PMID: 21076408) Nat Med. 2015 Sep;21(9):998-1009. (PMID: 26236991) Mol Med. 2021 Sep 9;27(1):106. (PMID: 34503454) Cell Mol Life Sci. 2009 Apr;66(7):1239-56. (PMID: 19099192) Aging (Albany NY). 2018 Feb 4;10(2):178-196. (PMID: 29410390) Front Immunol. 2023 Sep 06;14:1226962. (PMID: 37744330) Heliyon. 2022 Dec 12;8(12):e12078. (PMID: 36619469) Nucleic Acids Res. 2019 Sep 5;47(15):7719-7733. (PMID: 31328227) Autophagy. 2024 Jul 3;:1-18. (PMID: 38910554) Nat Commun. 2022 Jul 22;13(1):4255. (PMID: 35869084) Cell Res. 2017 Mar;27(3):315-328. (PMID: 28106072) J Cell Biochem. 2019 Jul;120(7):10884-10892. (PMID: 30756410) Cell Death Dis. 2022 Nov 23;13(11):987. (PMID: 36418856) J Clin Endocrinol Metab. 2019 Mar 1;104(3):665-673. (PMID: 30137347) Mol Ther. 2023 Nov 1;31(11):3225-3242. (PMID: 37735874) Front Mol Neurosci. 2023 Feb 21;16:1102147. (PMID: 36896007) Mol Ther. 2022 Apr 6;30(4):1721-1740. (PMID: 34995800) Mol Cell. 2013 Jan 10;49(1):18-29. (PMID: 23177736) Curr Opin Pharmacol. 2020 Dec;55:125-131. (PMID: 33232934) Elife. 2015 Nov 17;4:. (PMID: 26575292) FASEB J. 2024 Jan 31;38(2):e23409. (PMID: 38193628) Cell. 2012 Jun 22;149(7):1635-46. (PMID: 22608085) Cell Death Dis. 2021 Sep 27;12(10):881. (PMID: 34580283) Nat Cell Biol. 2018 Mar;20(3):285-295. (PMID: 29476152) Nature. 2016 May 25;534(7608):575-8. (PMID: 27281194) BMC Med Genet. 2008 Jul 03;9:59. (PMID: 18598350) Invest Ophthalmol Vis Sci. 2014 Oct 21;55(11):7321-31. (PMID: 25335984) Diabetologia. 2023 Jun;66(6):1084-1096. (PMID: 36920524) Exp Eye Res. 2021 Jul;208:108616. (PMID: 33979630) Cell. 2017 Nov 2;171(4):877-889.e17. (PMID: 28965759) Curr Mol Med. 2020;20(5):372-378. (PMID: 31702491) Cancer Lett. 2018 Apr 10;419:53-63. (PMID: 29371021) Am J Geriatr Psychiatry. 2023 Aug;31(8):583-585. (PMID: 37248116) Nutrients. 2023 Feb 04;15(4):. (PMID: 36839169) Cell Prolif. 2022 Jan;55(1):e13157. (PMID: 34821414) J Diabetes Complications. 2012 Sep-Oct;26(5):393-8. (PMID: 22770937) Mol Cell. 2019 Oct 3;76(1):70-81.e9. (PMID: 31445886) Int J Obes (Lond). 2018 Jul;42(7):1378-1388. (PMID: 29795461) Cell Mol Biol Lett. 2022 Jun 27;27(1):51. (PMID: 35761192) Endocrinology. 2019 Oct 1;160(10):2388-2394. (PMID: 31369074) EMBO Mol Med. 2024 Feb;16(2):294-318. (PMID: 38297099) Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2138-2148. (PMID: 31029827) Mol Med Rep. 2018 Sep;18(3):3513-3520. (PMID: 30066931) Protein Cell. 2022 Dec;13(12):877-919. (PMID: 34050894) Mol Cell. 2018 Sep 20;71(6):973-985.e5. (PMID: 30197295) Autophagy. 2023 Sep;19(9):2538-2557. (PMID: 37039556) Trends Genet. 2022 Apr;38(4):325-332. (PMID: 34920906) Curr Neuropharmacol. 2016;14(8):810-825. (PMID: 26997506) Acta Diabetol. 2023 Nov;60(11):1567-1580. (PMID: 37428236) Aging (Albany NY). 2024 Jan 29;16(2):1237-1248. (PMID: 38289593) BMC Nephrol. 2022 Mar 30;23(1):124. (PMID: 35354439) Gene. 2024 Mar 10;898:148130. (PMID: 38181926) Kidney Int Rep. 2022 Oct 17;8(1):36-50. (PMID: 36644366) Nature. 2015 Feb 26;518(7540):560-4. (PMID: 25719671) J Hematol Oncol. 2019 Nov 22;12(1):121. (PMID: 31757221) Int J Mol Sci. 2022 Mar 30;23(7):. (PMID: 35409166) Front Genet. 2022 Jun 28;13:908976. (PMID: 35836571) Nat Rev Clin Oncol. 2023 Aug;20(8):507-526. (PMID: 37221357) Nature. 2016 Sep 15;537(7620):369-373. (PMID: 27602518) J Diabetes Res. 2020 Jul 31;2020:3920196. (PMID: 32832560) |
| فهرسة مساهمة: | Keywords: DM; N6-methyladensine; eraser; microvascular complications; reader; writer |
| المشرفين على المادة: | JAC85A2161 (Adenine) |
| تواريخ الأحداث: | Date Created: 20240919 Date Completed: 20240919 Latest Revision: 20240920 |
| رمز التحديث: | 20240920 |
| مُعرف محوري في PubMed: | PMC11408340 |
| DOI: | 10.3389/fendo.2024.1462146 |
| PMID: | 39296713 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-2392 |
|---|---|
| DOI: | 10.3389/fendo.2024.1462146 |